• Korean
  • Chinese
表紙
市場調査レポート - 199968

世界のアルツハイマー病市場:パイプライン薬分析、市場分析・予測

Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis

発行 Renub Research
出版日 ページ情報 英文 110 Pages
価格
世界のアルツハイマー病市場:パイプライン薬分析、市場分析・予測 Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis
出版日: 2013年12月02日 ページ情報: 英文 110 Pages
概要

世界のアルツハイマー病治療薬の市場は、2009年以降持続的に縮小しています。しかし、2017年からは新薬の発売開始により回復に転じると予想されています。それでも、適確な治療薬がまだ無いことから、2018年の段階でも市場規模はアンメットニーズの10%程度に過ぎないものと思われます。

当レポートでは、アルツハイマー病の罹患動向と地域別動向、主要薬剤の将来的シナリオなどをまとめ、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

第2章 世界のアルツハイマー病治療薬市場の分析

  • アルツハイマー病治療薬の市場とその予測
  • アンメット市場とその予測(市場可能性)

第3章 失敗したアルツハイマー病治療薬

  • みじめな結果と再度の試み

第4章 世界市場シェアとその予測

第5章 ブランド別の市場実績:過去・現在・未来の市場

  • Exelon(リバスチグミン)
  • Aricept(ドネペジル)
  • メマンチン (Namenda, Ebixa, Axura, Memary)
  • Nootropil(ピラセタム)

第6章 パイプライン薬剤分析

  • Solanezumab (LY2062430):Eli Lilly
    • 治験の段階
      • 第II相
      • 第III相
    • 予想売上高
    • 近年の治験の動き
  • LuAE58054:Lundbeck
    • 治験の段階
      • 第II相
    • 予想売上高
    • 関連する資本取引
  • Gantenerumab:Roche
    • 治験の段階
      • 第I相
      • 第II & III相
      • 第III相
    • 関連の投資動向
  • Crenezumab:Genentech
    • 治験の段階
      • 第II相
    • 関連の投資動向
  • TRx0237 (LMTX):TauRx Therapeutics Ltd.
    • 治験の段階
      • 第II相
      • 第III相
    • 関連の投資動向
  • MK-8931:Merck
    • 治験の段階
      • 第II/III相
  • ABT-126:AbbVie
    • 治験の段階
      • 第I相
      • 第II相
  • AZD-1446:Targacept/AstraZeneca
    • 治験の段階
      • 第I相
    • 近年の開発動向

第7章 企業合併・買収(M&A)・ライセンス契約・戦略提携・共同事業契約の動向

  • 戦略提携
  • ライセンス契約
  • 共同事業契約
  • 企業合併・買収(M&A)

第8章 アルツハイマー病治療薬研究への資金供給

  • 米国国立保健研究所
  • Alzheimer's Association
  • Cure Alzheimer's Fund
  • Alzheimer's Drug Discovery Foundation
  • BrightFocus Foundation(旧American Health Assistance Foundation (AHAF))

第9章 主な成長促進要因

  • 人口高齢化
    • 世界の高齢化の指標
    • 高齢者人口(60歳以上):全世界および発展途上国(1950〜2050年)
    • 高齢者(60歳以上)の人口分布:年齢層別(全世界、1950〜2050年)
  • アンメット・メディカル・ニーズ
  • 新規薬剤(Solanezumab、LuAE58054、Gantenerumab、TRx0237)の発売による、市場の長期的な促進
  • 未来のアルツハイマー病の修飾薬

第10章 市場の主な課題

  • 検証された標的不足と動物モデルの不足
  • 治験の設計・実施に際しての障壁
  • 学術的、法的問題における障壁
  • 治療薬開発の失敗:神経科学の今後の研究開発(R&D)への当て擦り
  • 高額の開発費用のため、製薬企業が及び腰となる
  • 研究の後退と飛び石

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

From the year 2009 Alzheimer's disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer's drugs from the year 2017 onwards, Alzheimer's disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer's Drug Market. For the year 2018 Alzheimer's Disease Drug Market will be just 10% of Unmet Alzheimer's Disease Drug Market.

Renub Research study titled "Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis " provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer's Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer's Disease Drug Market.

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. Worldwide - Alzheimer's Disease Drug Market Analysis

  • 2.1 Alzheimer's Disease Drug Market & Forecast
  • 2.2 Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential)

3. Failed Alzheimer's Drugs

  • 3.1 Dismal Results but Still Trying Again

4. Worldwide - Alzheimer's Disease Drug Market Share & Forecast

5. Worldwide - Alzheimer's Drug Brands Market Performance

  • 5.1 Exelon (Rivastigmine) - Past, Present & Future Market
  • 5.2 Aricept (Donepezil) - Past, Present & Future Market
  • 5.3 Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market
    • 5.3.1 Namenda (Memantine) - Past, Present & Future Market
    • 5.3.2 Ebixa (Memantine) - Past, Present & Future Market
    • 5.3.3 Axura (Memantine) - Past, Present & Future Market
    • 5.3.4 Memary (Memantine) - Past, Present & Future Market
  • 5.4 Nootropil (Piracetam) - Past, Present & Future Market

6. Pipeline Drugs Analysis in Alzheimer's Disease Market

  • 6.1 Solanezumab (LY2062430) - Eli Lilly
    • 6.1.1 Clinical Development Stage
      • 6.1.1.1 Phase - II
      • 6.1.1.2 Phase - III
    • 6.1.2 Solanezumab Drug Sales (2017 - 2020)
    • 6.1.3 Recent Clinical Development
  • 6.2 LuAE58054 - Lundbeck
    • 6.2.1 Clinical Development Stage
      • 6.2.1.1 Phase - II
    • 6.2.2 LuAE58054 Drug Sales (2017 - 2018)
    • 6.2.3 Deal on LuAE58054
  • 6.3 Gantenerumab - Roche
    • 6.3.1 Clinical Development Stage
      • 6.3.1.1 Phase - I
      • 6.3.1.2 Phase - II & III
      • 6.3.1.3 Phase - III
    • 6.3.2 Investment in Gantenerumab Drug
  • 6.4 Crenezumab - Genentech
    • 6.4.1 Clinical Development Stage
      • 6.4.1.1 Phase - II
    • 6.4.2 Investment in Crenezumab Drug
  • 6.5 TRx0237 (LMTX) - TauRx Therapeutics Ltd.
    • 6.5.1 Clinical Development Stage
      • 6.5.1.1 Phase - II
      • 6.5.1.2 Phase - III
    • 6.5.2 Investment in TRx0237 (LMTX) Drug
  • 6.6 MK-8931 - Merck
    • 6.6.1 Clinical Development Stage
      • 6.6.1.1 Phase - II/III
  • 6.7 ABT-126 - AbbVie
    • 6.7.1 Clinical Development Stage
      • 6.7.1.1 Phase - I
      • 6.7.1.2 Phase - II
  • 6.8 AZD-1446 - Targacept/AstraZeneca
    • 6.8.1 Clinical Development Stage
      • 6.8.1.1 Phase - I
    • 6.8.2 Recent Development

7. M&A, Licensing Agreement, Strategic Alliances & Collaboration Deals in Alzheimer's Disease Drug Market

  • 7.1 Strategic Alliances in Alzheimer's Disease Drug Market
  • 7.2 Licensing Agreement in Alzheimer's Disease Drug Market
  • 7.3 Collaboration Deal in Alzheimer's Disease Drug Market
  • 7.4 Merger & Acquisition in Alzheimer's Disease Drug Market

8. Funding in Alzheimer's Disease Drugs Research

  • 8.1 National Institute of Health
  • 8.2 Alzheimer's Association
  • 8.3 Cure Alzheimer's Fund
  • 8.4 Alzheimer's Drug Discovery Foundation
  • 8.5 BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]

9. Key Drivers of Growth in Global Alzheimer's Disease Drug Market

  • 9.1 Aging Population
    • 9.1.1 Global Ageing Indicators
    • 9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
    • 9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
  • 9.2 Unmet Medical Needs
  • 9.3 The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost the Alzheimer's Market Through 2018
  • 9.4 Future Drugs for Disease Modification in Alzheimer's Disease

10. Key Challenges in the Global Alzheimer's Disease Drug Market

  • 10.1 Lack of Validated Targets & Lack of Animal Models
  • 10.2 Barriers in the Design and Implementation of Clinical Trials
  • 10.3 Barriers in Academia & Regulatory Issues
  • 10.4 Alzheimer's Drug Failure: Insinuation for Future R&D in Neuroscience
  • 10.5 Costly Alzheimer's Drug Development Dissuade Drug Companies
  • 10.6 Research Setbacks and Stepping Stones

List of Figures:

  • Figure 2 1: Worldwide - Alzheimer's Disease Drug Market (Million US$), 2003 - 2012
  • Figure 2 2: Worldwide - Forecast for Alzheimer's Disease Drug Market (Million US$), 2013 - 2018
  • Figure 2 3: Worldwide - Unmet Alzheimer's Disease Drug Market (Million US$), 2010 - 2012
  • Figure 2 4: Worldwide - Forecast for Unmet Alzheimer's Disease Drug Market (Million US$), 2013 - 2018
  • Figure 5 1: Worldwide - Exelon Alzheimer's Drug Sales (Million US$), 2005 - 2012
  • Figure 5 2: Worldwide - Forecast for Exelon Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 3: Worldwide - Aricept Alzheimer's Drug Sales (Million US$), 2004 - 2012
  • Figure 5 4: Worldwide - Forecast for Aricept Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 5: Worldwide - Namenda Alzheimer's Drug Sales (Million US$), 2003 - 2012
  • Figure 5 6: Worldwide - Forecast for Namenda Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 7: Worldwide - Ebixa Alzheimer's Drug Sales (Million US$), 2003 - 2012
  • Figure 5 8: Worldwide - Forecast for Ebixa Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 9: Worldwide - Axura Alzheimer's Drug Sales (Million US$), 2003 - 2012
  • Figure 5 10: Worldwide - Forecast for Axura Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 11: Worldwide - Memary Alzheimer's Drug Sales (Million US$), 2011 - 2012
  • Figure 5 12: Worldwide - Forecast for Memary Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 5 13: Worldwide - Nootropil Alzheimer's Drug Sales (Million US$), 2004 - 2012
  • Figure 5 14: Worldwide - Forecast for Nootropil Alzheimer's Drug Sales (Million US$), 2013 - 2018
  • Figure 6 1: Worldwide - Forecast for Pipeline Solanezumab Drug Sales (Million US$), 2017 - 2020
  • Figure 6 2: Worldwide - Forecast for Pipeline LuAE58054 Drug Sales (Million US$), 2017 - 2018
  • Figure 8 1: National Institute of Health - Funding in Alzheimer's Disease Research (Million US$), 2003 - 2013
  • Figure 8 2: Alzheimer's Association - Funding in Alzheimer's Disease Research (Million US$), 2007 - 2013
  • Figure 8 3: Cure Alzheimer's Fund - Funding in Alzheimer's Disease Research (Million US$), 2007 - 2012
  • Figure 8 4: Alzheimer's Drug Discovery Foundation - Funding in Alzheimer's Disease Research (Million US$), 2007 - 2012
  • Figure 9 1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
  • Figure 9 2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
  • Figure 9 3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
  • Figure 9 4: Worldwide - Pipeline Alzheimer's Drugs Performance (Million US$), 2009, 2015, 2017
  • Figure 10 1: Unsuccessful Alzheimer's Drug Development (Number), 1998 - 2011

List of Tables:

  • Table 4 1: Worldwide - Alzheimer's Disease Drug Market Share (Percent), 2003 - 2012
  • Table 4 2: Worldwide - Forecast for Alzheimer's Disease Drug Market Share (Percent), 2013 - 2018
  • Table 6 1: Alzheimer's Disease - Investment in Crenezumab Drug (Million US$), 2012
  • Table 7 1: Strategic Alliances in Alzheimer's disease Drug Market, 2003 - 2013
  • Table 7 2: Licensing Agreement in Alzheimer's disease Drug Market, 2007 - 2013
  • Table 7 3: Collaboration Deal in Alzheimer's Disease Drug Market, 2005 - 2013
  • Table 7 4: Merger & Acquisition (Million US$) in Alzheimer's disease Drug Market, 2008 - 2013
  • Table 8 1: BrightFocus Foundation - Funding in Alzheimer's disease Research (US$), 2010 - 2013
  • Table 9 1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
  • Table 9 2: Global - Population (Number), 2011/2012 - 2050
  • Table 9 3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100 (Medium Variant)
Back to Top